Vericel Corporation (VCEL)
| Market Cap | 2.94B +49.0% |
| Revenue (ttm) | 324.17M +25.3% |
| Net Income | 33.31M +154.6% |
| EPS | 0.62 +150.1% |
| Shares Out | 51.03M |
| PE Ratio | 93.25 |
| Forward PE | 67.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 582,337 |
| Open | 58.11 |
| Previous Close | 58.26 |
| Day's Range | 57.33 - 59.49 |
| 52-Week Range | 28.95 - 59.75 |
| Beta | 1.06 |
| Analysts | Strong Buy |
| Price Target | 65.43 (+13.75%) |
| Earnings Date | Nov 5, 2026 |
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic... [Read more]
Financial Performance
In 2025, Vericel's revenue was $276.26 million, an increase of 16.45% compared to the previous year's $237.22 million. Earnings were $16.52 million, an increase of 59.41%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price target is $65.43, which is an increase of 13.75% from the latest price.
News
Vericel Transcript: 2026 Stephens Annual Investment Conference | NASH2026
Q3 2026 revenue exceeded $85M, up 26% YoY, with records in MACI and burn care and sharply higher profitability. Biopsy momentum, a targeted UK launch in H2 2027, and commercial initiatives underpin the 2027 outlook.
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
BURLINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co...
Vericel price target raised to $68 from $55 at Stephens
Stephens analyst Mason Carrico raised the firm’s price target on Vericel (VCEL) to $68 from $55 and keeps an Overweight rating on the shares. The firm updated its FY26 and…
Vericel price target raised to $65 from $52 at Truist
Truist raised the firm’s price target on Vericel (VCEL) to $65 from $52 and keeps a Buy rating on the shares, citing “broad-based 3Q outperformance” and increased confidence in management’s…
Vericel price target raised to $63 from $58 at TD Cowen
TD Cowen raised the firm’s price target on Vericel (VCEL) to $63 from $58 and keeps a Buy rating on the shares. The firm updated its model following Q3 results.
Vericel price target raised to $75 from $72 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Vericel (VCEL) to $75 from $72 and keeps a Buy rating on the shares. The firm cites the “beat…
Vericel reports Q3 EPS 27c, consensus 6c
Reports Q3 revenue $85.37M, consensus $77.95M. “The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as w...
Vericel raises FY26 revenue view to $344M-$346M from $330M-$340M
Consensus $336.22M. Backs FY26 gross margin view 75%.
Vericel Earnings Call Transcript: Q3 2026
Q3 revenue rose 26% to $85.4M, with record results across MACI and burn care and adjusted EBITDA margin of 30%. FY revenue guidance increased to $344M-$346M as strong demand and commercial execution support continued growth.
Vericel Earnings release: Q3 2026
Vericel released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Vericel Slides: Q3 2026
Vericel has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Vericel Quarterly report: Q3 2026
Vericel has published its Q3 2026 quarterly earnings report on November 5, 2026.
Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% to $14.2 Million Adjusted EBITDA Margin of 30% Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Marg...
Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026
BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Co...
Vericel price target lowered to $52 from $58 at Truist
Truist lowered the firm’s price target on Vericel (VCEL) to $52 from $58 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Vericel Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
MACI continues to drive robust growth through OUS expansion, new indications, and procedural innovation, supported by a larger, more productive sales force and commercial excellence initiatives. Burn Care is gaining momentum, aided by the BARDA contract, while strong margins and cash flow enable both shareholder returns and further business development.
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026
BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the C...
Vericel price target raised to $58 from $55 at TD Cowen
TD Cowen raised the firm’s price target on Vericel (VCEL) to $58 from $55 and keeps a Buy rating on the shares. The firm said its Q2 beat and raise…
Vericel Earnings Call Transcript: Q2 2026
Record Q2 revenue and profitability exceeded guidance, driven by strong MACI and Burn Care growth. Full-year guidance was raised, a $200 million share repurchase was announced, and significant cash generation supports ongoing investments and capital returns.
Vericel Slides: Q2 2026
Vericel has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Vericel Earnings release: Q2 2026
Vericel released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Vericel Quarterly report: Q2 2026
Vericel has published its Q2 2026 quarterly earnings report on July 30, 2026.
Vericel reports Q2 EPS 4c, consensus (3c)
Reports Q2 revenue $77.46M, consensus $72.69M. “The Company delivered excellent financial and business results in the second quarter as we continue to generate top-tier revenue and profit growth as we...
Vericel raises FY26 revenue view to $330M-$340M from $326M-$336M
Consensus $332.2M. Reaffirms full-year profitability guidance of gross margin of approximately 75% and adjusted EBITDA margin of approximately 27%.
Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Mill...